This clinical trial focuses on Atrial Fibrillation, which is an irregular and often rapid heart rhythm condition. The study compares two heart rhythm medications: Etacizin and Propafenone. Both medications are taken orally in the form of tablets and belong to a group of drugs called antiarrhythmics, which help control irregular heartbeats.
The purpose of this research is to evaluate how well Etacizin works in maintaining normal heart rhythm in patients with atrial fibrillation compared to Propafenone over a six-month period. The study is open-label, which means both patients and doctors will know which medication is being used during treatment.
During the study, participants will receive either Etacizin (up to 200 mg daily) or Propafenone (up to 900 mg daily) for approximately seven months. The research will monitor how well these medications prevent the return of irregular heart rhythm after normal heart rhythm has been restored. The study will also track other important factors such as quality of life and heart-related health events during the treatment period.



Latvia